Recent News

• 03.12.2026 - Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
• 03.11.2026 - Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
• 03.09.2026 - Xenon Pharmaceuticals Announces Proposed Public Offering
• 03.09.2026 - Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
• 03.08.2026 - Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

Recent Filings

• 03.12.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.12.2026 - 8-K Current report
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2026 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 03.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2026 - 144 Report of proposed sale of securities
• 03.10.2026 - 144 Report of proposed sale of securities
• 03.10.2026 - 144 Report of proposed sale of securities
• 03.09.2026 - EX-99.1 EX-99.1